As governments across the world grapple with the ongoing COVID-19 (coronavirus), the India Health Fund (IHF) is inviting applications from innovators to address respiratory and airborne infections through its nation-wide search, Quest 2020. Such initiatives are encouraging effective solutions addressing respiratory disorders treatment. Thus, governments in other countries such as the U.S., Italy, and Spain can take cues from such nation-wide initiatives that can help to control COVID-19.
Since coronavirus directly affects the respiratory system of patients, governments, and laboratories have accelerated their research to minimize the severity of the virus among the affected and new patients. Ongoing R&D activities hold promising potential for innovations in the respiratory disorders treatment market. Top-tier companies in India are extending their arms to fund government initiatives in respiratory disorders treatment market. These initiatives are prioritizing the identification and diagnosis of coronavirus. There is a growing need for pre-validated solutions that can be extended for the treatment of coronavirus and other respiratory conditions.
There is a growing demand for handheld devices capable of detecting biomarkers and molecules that deploy instant feedback on respiratory disorders. Hence, NOWA Innovations-a University of California, Irvine (UCI) startup, has introduced Unaresp™, a novel device that identifies inhaled medication concentrations and trains patients to correctly inhale medications. Such innovations are anticipated to boost the expansion of the respiratory disorders treatment market, where the market is expected to reach ~US$ 108 Bn by 2027.
Companies in the respiratory disorders treatment market are increasing their R&D capabilities to develop devices that deliver information about the quality of the patient’s exhalation and the probability of an inflamed airway. Thus, useful information on airway and breath quality is predicted to improve patient outcomes in the respiratory disorders treatment market. Companies in the market for respiratory disorders treatment are increasing efforts to fast-track the device’s approval with the FDA for future commercialization.
The concept of lung microbiome is acquiring popularity in the respiratory disorders treatment market. Since some of the microorganisms in lungs are uninvited gatecrashers, lung microbiome helps to provide information about the status of an individual’s disease status.
Lung microbiome is as unique as an individual’s fingerprint, thus resulting in guided individual treatment decisions that help improve patient quality of life. The novel technique also has the potential to guide companies in the respiratory disorders treatment market to develop new medicines. As such, modern laboratory techniques are being deployed to gain information about the quantity and specificity of bacteria present in the sputum samples of individuals.
Several factors such as different organisms moving into the airways as well as environmental factors determine the composition of the lung microbiome among individuals. Thus, the importance of ‘friendly’ gut bacteria is gaining widespread acceptance for respiratory disorders treatment. Healthcare providers in the market of respiratory disorders treatment can increase their efficacy in lung microbiome to identify the symptoms and perhaps decipher the slow progression of respiratory infections.
Asthma is one of the most common non-communicable disease among children, with a high prevalence worldwide. This is evident since asthma dictates the highest revenue among all diseases in the respiratory disorders treatment market, where the market estimated to progress at a healthy CAGR of ~6% during the forecast period. However, challenges concerning non-availability of equipment and medications for the treatment of asthma in low-resource settings pose as a barrier for market growth. Hence, companies in the respiratory disorders treatment market should increase their production capabilities to meet the demands of healthcare facilities in low-income countries.
Sufficient availability of equipment and necessary medications helps healthcare professionals to differentiate between common respiratory conditions such as pneumonia and asthma versus self-limiting viral infections. Apart from this, there is a growing awareness about non-pharmacological interventions that are underutilized, but can ease symptoms of patients requiring respiratory disorders treatment.
Analysts’ Viewpoint
Given the current public health exigencies amidst the COVID-19 crisis, nation-wide search programs inviting innovators to showcase pre-validated solutions are helping to control the virus. The concept of lung microbiome is acquiring widespread acceptance in the respiratory disorders treatment market to demonstrate how microbiomes are associated with other disorders such as cancer, stroke, and obesity.
Non-pharmacological interventions such as cognitive behavioral techniques are helping to improve the quality of life of chronic obstructive pulmonary disease (COPD) patients. However, there is a need to educate asthma and COPD patients on how to take their medications, which is one of the biggest issues that companies face. Hence, companies should gain expertise in devices that train patients on how to properly inhale their medications.
The global respiratory disorders treatment market was worth US$ 65 Bn and is projected to reach a value of US$ 108 Bn by the end of 2026
Respiratory disorders treatment market is anticipated to grow at a CAGR of 6% during the forecast period
North America accounted for a major share of the global respiratory disorders treatment market
Respiratory disorders treatment market is driven by increase in incidence of respiratory disorders, surge in supportive care products to meet the rise in demand for treatment of respiratory disorders and entry of new players
Key players in the global respiratory disorders treatment market include Mylan N.V, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Sanofi, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries, CHIESI Farmaceutici S.p.A., Cipla, Vertex Pharmaceuticals Incorporated
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Respiratory Disorders Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Route of Administration Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Respiratory Disorders Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Bn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Health Care Industry Overview
5.2. Health Care Industry Overview
5.3. Pipeline Analysis (asthma, lung cancer, COPD)
5.4. Disease Prevalence Rate in Key Countries
5.5. Disease Management
5.6. Key Market Events
5.7. Regulatory Scenario
5.8. Reimbursement Scenario
5.9. Technological Advancements
6. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Respiratory Disorders Treatment Market Value Forecast, by Drug Class, 2017–2027
6.2.1. Bronchodilators
6.2.2. Corticosteroids
6.2.3. Combination Drugs
6.2.4. Antibiotics
6.2.5. Target Therapy
6.2.6. Immunotherapy
6.2.7. CFTR
6.3. Others Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class
7. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Disease
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Respiratory Disorders Treatment Market Value Forecast, by Disease, 2017–2027
7.2.1. Asthma
7.2.2. Chronic Obstructive Pulmonary Disease (COPD)
7.2.3. Lung Cancer
7.2.4. Respiratory Tract Infection
7.2.5. Allergic Rhinitis
7.2.6. Cystic Fibrosis (CF)
7.2.7. Others
7.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease
8. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Global Respiratory Disorders Treatment Market Value Forecast, by Route of Administration, 2017–2027
8.2.1. Oral
8.2.2. Nasal
8.2.3. Injectable
8.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration
9. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.1.1. Key Findings / Developments
9.2. Global Respiratory Disorders Treatment Market Value Forecast, by Distribution Channel, 2017–2027
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel
10. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Respiratory Disorders Treatment Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Region
11. North America Respiratory Disorders Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
11.2.1. Bronchodilators
11.2.2. Corticosteroids
11.2.3. Combination Drugs
11.2.4. Antibiotics
11.2.5. Target Therapy
11.2.6. Immunotherapy
11.2.7. CFTR
11.3. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
11.3.1. Asthma
11.3.2. Chronic Obstructive Pulmonary Disease (COPD)
11.3.3. Lung Cancer
11.3.4. Respiratory Tract Infection
11.3.5. Allergic Rhinitis
11.3.6. Cystic Fibrosis (CF)
11.3.7. Others
11.4. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
11.4.1. Oral
11.4.2. Nasal
11.4.3. Injectable
11.5. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America Respiratory Disorders Treatment Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Disease
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Respiratory Disorders Treatment Market Analysis and Forecast
12.1. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
12.1.1. Bronchodilators
12.1.2. Corticosteroids
12.1.3. Combination Drugs
12.1.4. Antibiotics
12.1.5. Target Therapy
12.1.6. Immunotherapy
12.1.7. CFTR
12.2. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
12.2.1. Asthma
12.2.2. Chronic Obstructive Pulmonary Disease (COPD)
12.2.3. Lung Cancer
12.2.4. Respiratory Tract Infection
12.2.5. Allergic Rhinitis
12.2.6. Cystic Fibrosis (CF)
12.2.7. Others
12.3. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
12.3.1. Oral
12.3.2. Nasal
12.3.3. Injectable
12.4. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
12.5.1. Germany
12.5.2. U.K.
12.5.3. France
12.5.4. Spain
12.5.5. Italy
12.5.6. Rest of Europe
12.6. Europe Respiratory Disorders Treatment Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Disease
12.6.3. By Route of Administration
12.6.4. By Distribution Channel
12.6.5. By Country/Sub-region
13. Asia Pacific Respiratory Disorders Treatment Market Analysis and Forecast
13.1. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
13.1.1. Bronchodilators
13.1.2. Corticosteroids
13.1.3. Combination Drugs
13.1.4. Antibiotics
13.1.5. Target Therapy
13.1.6. Immunotherapy
13.1.7. CFTR
13.2. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
13.2.1. Asthma
13.2.2. Chronic Obstructive Pulmonary Disease (COPD)
13.2.3. Lung Cancer
13.2.4. Respiratory Tract Infection
13.2.5. Allergic Rhinitis
13.2.6. Cystic Fibrosis (CF)
13.2.7. Others
13.3. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
13.3.1. Oral
13.3.2. Nasal
13.3.3. Injectable
13.4. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
13.5.1. China
13.5.2. Japan
13.5.3. India
13.5.4. Australia & New Zealand
13.5.5. Rest of Asia Pacific
13.6. Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Disease
13.6.3. By Route of Administration
13.6.4. By Distribution Channel
13.6.5. By Country/Sub-region
14. Latin America Respiratory Disorders Treatment Market Analysis and Forecast
14.1. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
14.1.1. Bronchodilators
14.1.2. Corticosteroids
14.1.3. Combination Drugs
14.1.4. Antibiotics
14.1.5. Target Therapy
14.1.6. Immunotherapy
14.1.7. CFTR
14.2. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
14.2.1. Asthma
14.2.2. Chronic Obstructive Pulmonary Disease (COPD)
14.2.3. Lung Cancer
14.2.4. Respiratory Tract Infection
14.2.5. Allergic Rhinitis
14.2.6. Cystic Fibrosis (CF)
14.2.7. Others
14.3. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
14.3.1. Oral
14.3.2. Nasal
14.3.3. Injectable
14.4. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
14.5.1. Brazil
14.5.2. Mexico
14.5.3. Rest of Latin America Latin America
14.6. Latin America Respiratory Disorders Treatment Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Disease
14.6.3. By Route of Administration
14.6.4. By Distribution Channel
14.6.5. By Country/Sub-region
15. Middle East & Africa Respiratory Disorders Treatment Market Analysis and Forecast
15.1. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
15.1.1. Bronchodilators
15.1.2. Corticosteroids
15.1.3. Combination Drugs
15.1.4. Antibiotics
15.1.5. Target Therapy
15.1.6. Immunotherapy
15.1.7. CFTR
15.2. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
15.2.1. Asthma
15.2.2. Chronic Obstructive Pulmonary Disease (COPD)
15.2.3. Lung Cancer
15.2.4. Respiratory Tract Infection
15.2.5. Allergic Rhinitis
15.2.6. Cystic Fibrosis (CF)
15.2.7. Others
15.3. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
15.3.1. Oral
15.3.2. Nasal
15.3.3. Injectable
15.4. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
15.4.1. Hospital Pharmacies
15.4.2. Retail Pharmacies
15.4.3. Online Pharmacies
15.5. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
15.5.1. GCC Countries
15.5.2. South Africa
15.5.3. Rest of Middle East & Africa
15.6. Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis
15.6.1. By Drug Class
15.6.2. By Disease
15.6.3. By Route of Administration
15.6.4. By Distribution Channel
15.6.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by Tier and Size of companies)
16.2. Market Share / Position Analysis, by Company, 2018
16.3. Competitive Business Strategies
16.4. Company Profiles
16.4.1. GlaxoSmithKline plc
16.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.1.2. Growth Strategies
16.4.1.3. SWOT Analysis
16.4.2. Merck & Co., Inc.
16.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.2.2. Growth Strategies
16.4.2.3. SWOT Analysis
16.4.3. AstraZeneca
16.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.3.2. Growth Strategies
16.4.3.3. SWOT Analysis
16.4.4. Boehringer Ingelheim International GmbH
16.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.4.2. Growth Strategies
16.4.4.3. SWOT Analysis
16.4.5. Novartis AG
16.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.5.2. Growth Strategies
16.4.5.3. SWOT Analysis
16.4.6. F. Hoffmann-La Roche Ltd.
16.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.6.2. Growth Strategies
16.4.6.3. SWOT Analysis
16.4.7. Teva Pharmaceutical Industries Ltd.
16.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.7.2. Growth Strategies
16.4.7.3. SWOT Analysis
16.4.8. Sanofi
16.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.8.2. Growth Strategies
16.4.8.3. SWOT Analysis
16.4.9. Cipla, Inc.
16.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.9.2. Growth Strategies
16.4.9.3. SWOT Analysis
16.4.10. Sun Pharmaceutical Industries Ltd.
16.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.10.2. Growth Strategies
16.4.10.3. SWOT Analysis
16.4.11. Mylan N.V.
16.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.11.2. Growth Strategies
16.4.11.3. SWOT Analysis
16.4.12. Takeda Pharmaceutical Company Limited
16.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.12.2. Growth Strategies
16.4.12.3. SWOT Analysis
16.4.13. CHIESI Farmaceutici S.p.A.
16.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.13.2. Growth Strategies
16.4.13.3. SWOT Analysis
16.4.14. Orion Corporation
16.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.14.2. Growth Strategies
16.4.14.3. SWOT Analysis
16.4.15. Vertex Pharmaceutical
16.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.15.2. Growth Strategies
16.4.15.3. SWOT Analysis
List of Tables
Table 01: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 02: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 03: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 04: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 05: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Region, 2017–2027
Table 06: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2027
Table 07: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 08: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 09: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 10: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 11: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
Table 12: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 13: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 14: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 15: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 16: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 18: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 19: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 20: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 21: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 23: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 24: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 25: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 26: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
Table 27: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 28: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 29: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 30: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 01: Global Respiratory Disorders Treatment Market Value (US$ Bn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, 2017–2027
Figure 03: Global Respiratory Disorders Treatment Market Value Share (%), by Drug Class, 2018
Figure 04: Global Respiratory Disorders Treatment Market Value Share (%), by Disease, 2018
Figure 05: Global Respiratory Disorders Treatment Market Value Share (%), by Route of Administration, 2018
Figure 06: Global Respiratory Disorders Treatment Market Value Share (%), by End-user, 2018
Figure 07: Global Respiratory Disorders Treatment Market Value Share (%), by Region, 2018
Figure 08: Global Respiratory Disorders Treatment Market Value Share (%), by Drug Class, 2018 and 2027
Figure 09: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 10: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Bronchodilators, 2017–2027
Figure 11: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2027
Figure 12: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Combination Drugs, 2017–2027
Figure 13: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Antibiotics, 2017–2027
Figure 14: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Target Therapy, 2017–2027
Figure 15: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Immunotherapy, 2017–2027
Figure 16: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by CFTR, 2017–2027
Figure 17: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 18: Global Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027
Figure 19: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 20: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Asthma, 2017–2027
Figure 21: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Chronic Obstructive Pulmonary Disease (COPD), 2017–2027
Figure 22: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Lung Cancer, 2017–2027
Figure 23: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Respiratory Tract Infection, 2017–2027
Figure 24: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Allergic Rhinitis, 2017–2027
Figure 25: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Cystic Fibrosis (CF), 2017–2027
Figure 26: Global Respiratory Disorders Treatment Market Revenue (US$ Bn), by Others, 2017–2027
Figure 27: Global Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027
Figure 28: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 29: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Oral, 2017–2027
Figure 30: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Nasal, 2017–2027
Figure 31: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Injectable, 2017–2027
Figure 32: Global Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027
Figure 33: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 34: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 35: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 36: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027
Figure 37: Global Respiratory Disorders Treatment Market Value Share (%) Analysis, by Region, 2018 and 2027
Figure 38: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 39: North America Respiratory Disorders Treatment Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 40: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Country, 2018 and 2027
Figure 41: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Country, 2019–2027
Figure 42: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027
Figure 43: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 44: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027
Figure 45: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 46: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027
Figure 47: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 48: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027
Figure 49: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 50: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 51: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Country/Sub-Region, 2018 and 2027
Figure 52: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 53: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027
Figure 54: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 55: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027
Figure 56: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 57: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027
Figure 58: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 59: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027
Figure 60: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 61: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 62: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Country/Sub-region, 2018 and 2027
Figure 63: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 64: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027
Figure 65: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 66: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027
Figure 67: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 68: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027
Figure 69: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 70: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027
Figure 71: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 72: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 73: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Country/Sub-region, 2018 and 2027
Figure 74: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 75: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027
Figure 76: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 77: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027
Figure 78: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 79: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027
Figure 80: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 81: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027
Figure 82: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 83: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 84: Middle East & Africa Respiratory Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 85: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 86: Middle East & Africa Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027
Figure 87: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 88: Middle East & Africa Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027
Figure 89: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027
Figure 90: Middle East & Africa Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027
Figure 91: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027
Figure 92: Middle East & Africa Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027
Figure 93: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Respiratory Disorders Treatment Market
